Corrigendum to“The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection:A review”[J.Pharma.Anal.11(2021)265-271]

Leonny Dwi Rizkita,Indwiani Astuti

Department of Pharmacology and Therapy,Faculty of Medicine,Public Health and Nursing,Universitas Gadjah Mada,Yogyakarta,55281,Indonesia

Original statement in Section 3:

3.Host-pathogen interactions in SARS-CoV-2 infection

SARS-CoV-2 shares many of the same characteristics as most coronavirus family viruses,including a pleomorphic or spherical shaped capsid envelope 150-160 nm in size,a polycistronic mRNA with a 5＇cap and 3＇poly-A-tail,and an unsegmented,positive,single-stranded RNA genome(30 kb)[32-34].SARS-CoV-2 has two large polyproteins,ORF1a and ORF1b;four structural proteins:spike(S),envelope(E),membrane(M),and nucleocapsid(N);and eight accessory proteins:ORF3a,ORF3b,ORF6,ORF7a,ORF7b,ORF8a,ORF8b,and ORF9b.

Corrected statement in Section 3:

3.Host-pathogen interactions in SARS-CoV-2 infection

SARS-CoV-2 shares many of the same characteristics as most coronavirus family viruses,including a pleomorphic or spherical shaped capsid envelope 150-160 nm in size,a polycistronic mRNA with a 5＇cap and 3＇poly-A-tail,and an unsegmented,positive,single-stranded RNA genome(30 kb)[32-34].SARS-CoV-2 has two large polyproteins,ORF1a and ORF1b;four structural proteins:spike(S),envelope(E),membrane(M),and nucleocapsid(N);and some accessory proteins:ORF3a,ORF6,ORF7a,ORF7b,ORF8,and ORF10.

The authors regret to inform that the statement in our review paper regarding the eight accessory proteins of SARS-CoV-2 were wrong and correction has been made to support the current findings.

The authors would like to apologize for any inconvenience caused.